 "Exceptional gain pushes Strides Q4 net to Rs 3,525 cr")
On the back of an exceptional gain, the pharmaceutical company Strides Arcolab today reported a gigantic increase in net profit at Rs 3,525 crore for the quarter ended December 2013. It was Rs 74 crore in the same period a year ago.
The company made an exceptional gain of Rs 3,265 crore by selling Agila to Mylan.
The total income has increased five-fold to Rs 1,642 crore as against Rs 261 crore in December 2012.
On Friday at 1350 hours the company's stocks on BSE were trading 1.2% higher at Rs 384 apiece.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%